Niquitin Clear 21mg/24h 14 transdermal patches

Niquitin Clear 21mg/24h is indicated for the relief of nicotine withdrawal symptoms, including uncontrollable cravings associated with smoking cessation. If possible, when quitting, Niquitin Clear should be used as part of a behavioral support program. Niquitin Clear is indicated for adults and adolescents aged 12 years and over.

Active substances: 21mg/24h of nicotine.

Nicotine, the main alkaloid in tobacco products and a naturally occurring autonomous substance, is a nicotine receptor agonist in the central and peripheral nervous system. Nicotine has been shown to be addictive in tobacco consumption.

Dosage and method of administration:

Adults over 18 years of age: Before starting therapy, users must commit to quitting smoking. During a cessation attempt, every effort should be made to not smoke during treatment with Niquitin Clear. Simultaneous behavioral support is recommended, as this type of program has been shown to be beneficial for smoking cessation. In some cases (for example, in highly addicted smokers, smokers who have relapsed after NRT in the past, or in cases where one form of NRT is not sufficient to control smoking cravings, it may be beneficial to use more than one form of Niquitin simultaneously. Niquitin Clear transdermal patches can be used alone or in combination with Niquitin 1.5mg / 2mg / 4mg sucking tablets or chewing gums (see detailed combination therapy dosage in the package leaflet). Niquitin transdermal patches Clear should be applied once a day, at the same time each day, preferably shortly after waking up, and should be used continuously for 24 hours. Therapy with Niquitin Clear normally starts with Niquitin Clear 21 mg/24 h and then reduced according to the following dosage schedule: Phase 1 Niquitin Clear 21 mg/24 h - First 6 weeks; Phase 2 Niquitin Clear 14 mg/24 h - Subsequent 2 weeks; Phase 3 Niqui tin Clear 7 mg/24 h Last 2 weeks. Moderate smokers (those who smoke less than 10 cigarettes per day) are recommended to start with Phase 2 (14 mg/24 h) for 6 weeks and then move to Niquitin Clear 7 mg/24 h within the last 2 weeks. Patients taking Niquitin Clear 21 mg/24 h who have experienced excessive side effects that have not disappeared within a few days should switch to Niquitin Clear 14 mg/24 h. This dosage should then be maintained through the end of the first six weeks of Phase 1, before switching to Niquitin Clear 7 mg/24h for the last two weeks. If symptoms persist, the patient should be advised to consult a healthcare professional. A new Niquitin Clear patch should be applied to a clean, dry, hairless area of skin. Niquitin Clear should be applied immediately after it has been removed from its protective sachet. The patch should be kept closed in its protective sachet until ready to use. It should be pressed firmly into the skin with the palm of the hand for 10 seconds. Areas where the skin folds should be avoided. Application to cracked, red or irritated skin should be avoided. After 24 hours the used transdermal patch should be removed and a new patch applied to a different site on the skin. The same transdermal patch should not remain on the skin for more than 24 hours. Transdermal patches should not be placed on the same area of skin for at least seven days. Only one transdermal patch should be used at a time. If desired, the transdermal patch may be removed before bedtime. However, use for 24 hours is recommended to minimize the effects of morning cravings. Care must be taken during handling and in particular contact with eyes and nose must be avoided. After use, hands should only be washed with water as soap increases the absorption of nicotine.

Contraindications:

Hypersensitivity to the active substance(s) or to any of the excipients. Niquitin Clear transdermal patches should not be used by children under 12 years of age, occasional smokers and non-smokers.

If in doubt or if symptoms persist, consult your doctor or pharmacist.

In accordance with current legislation, non-prescription medicines in Portugal can only be delivered to the municipalities of Maia, Gondomar, Matosinhos, Porto, Santo Tirso, Trofa, Valongo and Vila do Conde. This limitation does not apply to shipments to other Member States of the European Union.